{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T21:02:42Z","timestamp":1778706162606,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Federation of National Public Service Personnel Mutual Aid Association"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Hyperammonemia is a serious adverse effect of 5-fluorouracil (5FU) administration. Hemodialysis can be used for its management, but detailed data on the concentrations and removal rate of 5FU and its metabolites during hemodialysis remain unclear. Here, we present two cases of hemodialysis patients with end-stage renal disease who received concurrent 5FU infusion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Blood samples were collected from the hemodialysis circuit before and after the dialyzer during day 2 hemodialysis sessions, and from the internal shunt just before and after day 4 hemodialysis sessions. The serum levels of 5FU and its metabolites\u2014\u03b1-fluoro-\u03b2-alanine (FBAL) and monofluoroacetate (FA)\u2014were measured using liquid chromatography-tandem mass spectrometry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seven sets of blood samples were collected for case 1; the removal rates (mean\u2009\u00b1\u2009standard deviation) of 5FU and FBAL by the dialyzer were 81.2\u2009\u00b1\u200923.2% and 96.1\u2009\u00b1\u20098.6%, respectively (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Three sets of blood samples were collected for case 2; the removal rates of 5FU and FBAL were 81.7\u2009\u00b1\u20093.9% and 94.8\u2009\u00b1\u20092.7%, respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.03). Twenty-seven sets of blood samples were collected for case 1; reductions in blood FBAL and FA levels were 49.3\u2009\u00b1\u20098.8% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and 64.2\u2009\u00b1\u200930.3% (<jats:italic>p<\/jats:italic>\u2009=\u20090.04), respectively. Bayesian estimation yielded similar results. Three sets of blood samples were collected for case 2; reductions in the blood FBAL and FA levels were 49.9\u2009\u00b1\u20096.9% and 50.6\u2009\u00b1\u200933.0%, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this study, 5FU and its metabolite FBAL were directly removed from the blood by approximately 90% during hemodialysis, and the blood levels of FBAL and FA were reduced by approximately 50% with a single hemodialysis session.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00280-023-04577-w","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T17:02:47Z","timestamp":1692723767000},"page":"161-167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Removal rate of 5-fluorouracil and its metabolites in patients on hemodialysis: a report of two cases of colorectal cancer patients with end-stage renal failure"],"prefix":"10.1007","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7603-6466","authenticated-orcid":false,"given":"Hirotaka","family":"Imamaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuaki","family":"Oura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiya","family":"Oguro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsaku","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Horimatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yonezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Muto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoko","family":"Yanagita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinao","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"key":"4577_CR1","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1053\/j.ajkd.2014.12.013","volume":"65","author":"AM Butler","year":"2015","unstructured":"Butler AM, Olshan AF, Kshirsagar AV, Edwards JK, Nielsen ME, Wheeler SB, Brookhart MA (2015) Cancer incidence among US medicare ESRD patients receiving hemodialysis, 1996\u20132009. Am J Kidney Dis 65:763\u2013772. https:\/\/doi.org\/10.1053\/j.ajkd.2014.12.013","journal-title":"Am J Kidney Dis"},{"key":"4577_CR2","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1093\/annonc\/mdp598","volume":"21","author":"N Janus","year":"2010","unstructured":"Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V (2010) Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 21:1395\u20131403. https:\/\/doi.org\/10.1093\/annonc\/mdp598","journal-title":"Ann Oncol"},{"key":"4577_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13613-022-01026-4","volume":"12","author":"A Balcerac","year":"2022","unstructured":"Balcerac A, Bihan K, Lebrun-Vignes B, Thabut D, Salem JE, Weiss N (2022) Drug-associated hyperammonaemia: a Bayesian analysis of the WHO Pharmacovigilance Database. Ann Intensive Care 12:55. https:\/\/doi.org\/10.1186\/s13613-022-01026-4","journal-title":"Ann Intensive Care"},{"key":"4577_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/jjco\/hye130","volume":"31","author":"YC Lin","year":"2001","unstructured":"Lin YC, Chen JS, Wang CH, Wang HM, Chang HK, Liaul CT, Yang TS, Liaw CC, Liu HE (2001) Weekly high-dose 5-fluorouracil (5-FU), leucovorin (LV) and bimonthly cisplatin in patients with advanced gastric cancer. Jpn J Clin Oncol 31:605\u2013609. https:\/\/doi.org\/10.1093\/jjco\/hye130","journal-title":"Jpn J Clin Oncol"},{"key":"4577_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00280-017-3249-1","volume":"79","author":"Y Nishikawa","year":"2017","unstructured":"Nishikawa Y, Funakoshi T, Horimatsu T, Miyamoto S, Matsubara T, Yanagita M, Nakagawa S, Yonezawa A, Matsubara K, Muto M (2017) Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. Cancer Chemother Pharmacol 79:629\u2013633. https:\/\/doi.org\/10.1007\/s00280-017-3249-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"4577_CR6","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/01.ftd.0000183384.89275.f4","volume":"27","author":"M Gusella","year":"2005","unstructured":"Gusella M, Rebeschini M, Cartei G, Ferrazzi E, Ferrari M, Padrini R (2005) Effect of hemodialysis on the metabolic clearance of 5-fluorouracil in a patient with end-stage renal failure. Ther Drug Monit 27:816\u2013818. https:\/\/doi.org\/10.1097\/01.ftd.0000183384.89275.f4","journal-title":"Ther Drug Monit"},{"key":"4577_CR7","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1681\/ASN.V451205","volume":"4","author":"JT Daugirdas","year":"1993","unstructured":"Daugirdas JT (1993) Second generation logarithmic estimates of single-pool variable volume Kt\/V: an analysis of error. J Am Soc Nephrol 4:1205\u20131213. https:\/\/doi.org\/10.1681\/ASN.V451205","journal-title":"J Am Soc Nephrol"},{"key":"4577_CR8","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00280-010-1400-3","volume":"67","author":"IRHM Konings","year":"2011","unstructured":"Konings IRHM, Sleijfer S, Mathijssen RHJ, De Bruijn P, Ghobadi Moghaddam-Helmantel IM, Van Dam LM, Wiemer EAC, Verweij J, Loos WJ (2011) Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study. Cancer Chemother Pharmacol 67:1055\u20131062. https:\/\/doi.org\/10.1007\/s00280-010-1400-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"4577_CR9","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00280-020-04158-1","volume":"86","author":"Y Ozaki","year":"2020","unstructured":"Ozaki Y, Imamaki H, Ikeda A, Oura M, Nakagawa S, Funakoshi T, Kataoka S, Nishikawa Y, Horimatsu T, Yonezawa A, Matsubara T, Yanagita M, Muto M, Watanabe N (2020) Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses. Cancer Chemother Pharmacol 86:693\u2013699. https:\/\/doi.org\/10.1007\/s00280-020-04158-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"4577_CR10","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1053\/ajkd.2002.30584","volume":"39","author":"J Rengelshausen","year":"2002","unstructured":"Rengelshausen J, Hull WE, Schwenger V, G\u00f6ggelmann C, Walter-Sack I, Bommer J (2002) Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis. Am J Kidney Dis 39:E10. https:\/\/doi.org\/10.1053\/ajkd.2002.30584","journal-title":"Am J Kidney Dis"},{"key":"4577_CR11","first-page":"483","volume":"40","author":"N Misumi","year":"2013","unstructured":"Misumi N, Goto T, Miyoshi T, Hiraike M, Shirasawa H, Saito O, Nishino T, Oudo M (2013) Risk factors for hyperammonemia during mFOLFOX6 treatment. Gan To Kagaku Ryoho 40:483\u2013487","journal-title":"Gan To Kagaku Ryoho"},{"key":"4577_CR12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/ki.2009.138","volume":"76","author":"J Mares","year":"2009","unstructured":"Mares J, Thongboonkerd V, Tuma Z, Moravec J, Matejovic M (2009) Specific adsorption of some complement activation proteins to polysulfone dialysis membranes during hemodialysis. Kidney Int 76:404\u2013413. https:\/\/doi.org\/10.1038\/ki.2009.138","journal-title":"Kidney Int"},{"key":"4577_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000321142","volume":"31","author":"Y Hirayama","year":"2011","unstructured":"Hirayama Y, Oda S, Wakabayashi K, Sadahiro T, Nakamura M, Watanabe E, Tateishi Y (2011) Comparison of interleukin-6 removal properties among hemofilters consisting of varying membrane materials and surface areas: an in vitro study. Blood Purif 31:18\u201325. https:\/\/doi.org\/10.1159\/000321142","journal-title":"Blood Purif"},{"key":"4577_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132539","volume":"10","author":"H Imamaki","year":"2015","unstructured":"Imamaki H, Ishii A, Yokoi H, Kasahara M, Kuwabara T, Mori KP, Kato Y, Kuwahara T, Satoh M, Nakatani K, Saito Y, Tomosugi N, Sugawara A, Nakao K, Mukoyama M, Yanagita M, Mori K (2015) Low serum neutrophil gelatinase-associated lipocalin level as a marker of malnutrition in maintenance hemodialysis patients. PLoS ONE 10:e0132539. https:\/\/doi.org\/10.1371\/journal.pone.0132539","journal-title":"PLoS ONE"},{"key":"4577_CR15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1046\/j.1365-2125.2003.01765.x","volume":"227","author":"JL Au","year":"1983","unstructured":"Au JL, Walker JS, Rustum Y (1983) Pharmacokinetic studies of 5-fluorouracil and 5\u2019-deoxy-5-fluorouridine in rats. J Pharmacol Exp Ther 227:174\u2013180. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.01765.x","journal-title":"J Pharmacol Exp Ther"},{"key":"4577_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1046\/j.1365-2125.2003.01765.x","volume":"55","author":"R Gieschke","year":"2003","unstructured":"Gieschke R, Burger HU, Reigner B, Blesch KS, Steimer JL (2003) Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol 55:252\u2013263. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.01765.x","journal-title":"Br J Clin Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04577-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04577-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04577-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T05:03:17Z","timestamp":1707368597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04577-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["4577"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04577-w","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,22]]},"assertion":[{"value":"16 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MO, FO, YN, SN, TF, SK, TH, AY, TM, NW, MM, MY, and YO have no conflicts of interest to disclose. HI received a speaker honorarium from Kyowa Kirin Co., Ltd., outside the submitted work. MY received research grants from\u00a0Mitsubishi Tanabe Pharma\u00a0and Boehringer Ingelheim.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the ethical review board of Hirakata Kohsai Hospital (approval number: 2019\u2013013).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the ethical review board of Hirakata Kohsai Hospital (approval number: 2019\u2013013).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving Human Participants and\/or Animals"}},{"value":"Written informed consent for these case reports was obtained from both patients.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Written informed consent for publication of this case report was obtained both from the patients and their children.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}